Overview

The Use of Intraperitoneal Ropivacaine in Bariatric Bypass Surgery

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This is a pilot study in a randomized, controlled, double-blinded format and will evaluate the ability of a local anesthetic, Ropivacaine, to decrease pain after gastric bypass surgery. The drug will be administered into the abdomen during a bariatric bypass surgery. After surgery, patients who received Ropivacaine will be compared to those without Ropivacaine to determine its effect on reducing pain, recovery of lung function, ability to walk, and quality of life during recovery.
Phase:
Phase 3
Details
Lead Sponsor:
Ottawa Hospital Research Institute
Treatments:
Ropivacaine